Clovis Oncology Inc. (CLVS)

57.78
2.10 3.50
NASDAQ : Health Technology
Prev Close 59.88
Open 59.97
Day Low/High 58.25 / 60.25
52 Wk Low/High 45.42 / 99.45
Volume 209.39K
Avg Volume 1.18M
Exchange NASDAQ
Shares Outstanding 49.02M
Market Cap 2.65B
EPS -9.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Even with Monday's sharp reversal, Jim Cramer says he still likes this market.

Clovis Oncology To Present At The 36th Annual J.P. Morgan Healthcare Conference

Clovis Oncology To Present At The 36th Annual J.P. Morgan Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Rucaparib MAA For The Ovarian Cancer Treatment Indication Referred By CHMP To Scientific Advisory Group On Oncology For Review Expected In February 2018

Rucaparib MAA For The Ovarian Cancer Treatment Indication Referred By CHMP To Scientific Advisory Group On Oncology For Review Expected In February 2018

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has requested that the Scientific Advisory Group...

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.

Clovis Announces Priority Review Designation For Rucaparib Supplemental New Drug Application

Clovis Announces Priority Review Designation For Rucaparib Supplemental New Drug Application

Clovis Oncology (NASDAQ: CLVS) announced today that the U.S.

Clovis Oncology To Present At The Stifel 2017 Healthcare Conference

Clovis Oncology To Present At The Stifel 2017 Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Notable Thursday Option Activity: CLVS, GOGO, ENDP

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Clovis Oncology Inc , where a total of 5,548 contracts have traded so far, representing approximately 554,800 underlying shares. That amounts to about 47.9% of CLVS's average daily trading volume over the past month of 1.2 million shares.

Clovis Oncology Announces Third Quarter 2017 Operating Results

Clovis Oncology Announces Third Quarter 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2017, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder...

Clovis Oncology To Announce Third Quarter 2017 Financial Results And Host Webcast Conference Call On November 1

Clovis Oncology To Announce Third Quarter 2017 Financial Results And Host Webcast Conference Call On November 1

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2017 financial results on Wednesday, November 1, 2017, after the close of the U.

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

In this sometimes fickle market, supply and demand are still at play.

Clovis Oncology Submits Supplemental New Drug Application For Rucaparib As Maintenance Treatment For Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Clovis Oncology Submits Supplemental New Drug Application For Rucaparib As Maintenance Treatment For Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Clovis Oncology (NASDAQ: CLVS) announced today that the company has submitted a supplemental New Drug Application (sNDA) to the U.

Clovis Oncology's Rucaparib ARIEL3 Study Data Published In The Lancet

Clovis Oncology's Rucaparib ARIEL3 Study Data Published In The Lancet

Clovis Oncology, Inc. (NASDAQ: CLVS) announced that comprehensive data from the Phase 3 ARIEL3 study of rucaparib for maintenance treatment of advanced ovarian cancer were published online today in The Lancet.

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

The company is scheduled Friday afternoon to present comprehensive data from its Phase 3 study of rucaparib at the European Society for Medical Oncology Congress in Madrid.

Clovis Oncology Presents Comprehensive Dataset From Successful Phase 3 ARIEL3 Maintenance Treatment Trial Of Rucaparib In Advanced Ovarian Cancer At ESMO 2017

Clovis Oncology Presents Comprehensive Dataset From Successful Phase 3 ARIEL3 Maintenance Treatment Trial Of Rucaparib In Advanced Ovarian Cancer At ESMO 2017

Clovis Oncology, Inc. (NASDAQ: CLVS) announced the first presentation of a comprehensive dataset from its Phase 3 ARIEL3 study of rucaparib at the 2017 European Society for Medical Oncology (ESMO) Congress taking place in...

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

More Immunotherapy Buyouts Likely After Kite Sale

Clovis Oncology To Present Comprehensive Dataset From Successful ARIEL3 Clinical Trial Program At 2017 ESMO Congress

Clovis Oncology To Present Comprehensive Dataset From Successful ARIEL3 Clinical Trial Program At 2017 ESMO Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstracts highlighting progress in the rucaparib clinical development program will be presented at the 2017 European Society for Medical Oncology (ESMO) Congress...

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of the hottest biotech stocks of the last month is selling off.

Clovis Oncology Announces Second Quarter 2017 Operating Results

Clovis Oncology Announces Second Quarter 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2017, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...

Clovis Sell-Off May Be Overdone

Clovis Sell-Off May Be Overdone

Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why

Several stocks spent Monday's trading session in the red, and here's why.

Clovis Oncology To Announce Second Quarter 2017 Financial Results And Host Webcast Conference Call On August 2

Clovis Oncology To Announce Second Quarter 2017 Financial Results And Host Webcast Conference Call On August 2

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2017 financial results on Wednesday, August 2, 2017, after the close of the U.

Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 511,363 shares.

Clovis Oncology Announces Upsizing And Pricing Of Public Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,409,091 shares of its common stock at $88.

Biotech Movers: AveXis, Clovis, Epizyme

Biotech Movers: AveXis, Clovis, Epizyme

AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.

Clovis Oncology Announces Proposed Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million.

Biotech Movers: Clovis, Seattle Genetics, Rigel

Biotech Movers: Clovis, Seattle Genetics, Rigel

Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19.

Clovis Oncology's Rucaparib Significantly Improved Progression-Free Survival In All Ovarian Cancer Patient Populations Studied In Phase 3 ARIEL3 Maintenance Treatment Trial

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by...